Open Access

Erratum to: EGFR and COX-2 protein expression in non-small cell lung cancer and the correlation with clinical features

Contributed equally
Journal of Experimental & Clinical Cancer Research201130:32

https://doi.org/10.1186/1756-9966-30-32

Received: 28 March 2011

Accepted: 28 March 2011

Published: 28 March 2011

The original article was published in Journal of Experimental & Clinical Cancer Research 2011 30:27

Correction

In the article [1] there were errors in Tables three, four, five, six and seven. The incorrect values were produced due to typographical errors during translation stage. These errors affect neither the published discussion nor the conclusions of the paper. However, a few changes to the results section are detailed here.

In the Abstract, under "Results" the first two sentences read

"The positive rate of EGFR protein in NSCLC tumor cells was 46%, which was significantly higher than its expression in normal lung (p = 0.0234) and paracancerous tissues (p = 0.020). EGFR expression was significantly higher in nodal positive than in nodal negative patients (p = 0.04)."

But should have been:

"The positive rate of EGFR protein in NSCLC tumor cells was 46%, which was significantly higher than its expression in normal lung (p = 0.034) and paracancerous tissues (p = 0.020). EGFR expression was significantly higher in nodal positive than in nodal negative patients (p = 0.006)."

In the main "Results" section of the article

The sentence under the heading "EGFR protein expression" read: "The positive rate of EGFR protein in NSCLC tumor cells were 46%, which was significantly higher than its expression in normal lung (p = 0.0234) and paracancerous (p = 0.020)"

Which should have been:

"The positive rate of EGFR protein in NSCLC tumor cells were 46%, which was significantly higher than its expression in normal lung (p = 0.034) and paracancerous (p = 0.020)"

Under the heading "Correlation between EGFR expression and clinical features" The second sentence read: "It shows that the difference of EGFR expression was only significant between the nodal positive and negative subgroups (56.4% vs.10%, p = 0.04)."

But the passage should have been "The expression of EGFR in different subgroups were compared and summarized in Table three. It shows that the difference of EGFR expression was only significant between the nodal positive and negative subgroups (56.4% vs. 9.1%, p = 0.006). There is no significant difference between age (60 vs. under 60 ys), gender, adeno- vs. non-adenocarcinoma, the differentiation of tumor, and staging."

This is the correct table three (table 1).
Table 1

(corrected table 3). EGFR expression and clinical characteristics

Clinical features

EGFR

Positive expression rate

P value

 

negative

positive

  

Ages

   

0.448

< 60

18

14

43.80%

 

≥60

9

9

50%

 

Sex

   

0.445

Male

16

15

48.40%

 

Female

11

8

42.10%

 

Pathologic type

   

0.543

Squamous carcinoma

13

8

38.10%

 

Adencarcinoma

13

13

50.0%

 

Mixed type

1

2

66.70%

 

Tumor length

   

0.535

≤3 cm

9

7

43.80%

 

> 3 cm

18

16

47.10%

 

Level of Differentiation

   

0.474

Poor Differentiated

6

4

40%

 

Moderate and Well Differentiated

21

19

47.50%

 

TNM Stage

   

0.194

I-II

10

5

33.30%

 

III-IV

17

18

51.40%

 

Lymph node

   

0.006*

N0

10

1

9.10%

 

N1-3

17

22

56.40%

 

*P < 0.05

Correct tables four (table 2), five (table 3) and six (table 4).
Table 2

(corrected table four) COX-2 expression in neoplastic and normal tissue

Tissue type

Number of cases

COX-2

Positive rate(%)

P value

  

negative

positive

  

Neoplastic tissue

50

45

5

90

0.000*

Normal tissue

6

0

6

0

 

P < 0.05

Table 3

(corrected table five) COX-2 expression in tumor and paracancerous tissue

Tissue type

Number of cases

COX-2

Positive rate(%)

P value

  

negative

positive

  

Neoplastic tissue

50

45

5

90

0.000*

Paracancerous tissue

7

1

6

14.3

 

P < 0.05

Table 4

(corrected table six) 6 COX-2 expression and correlation with clinical features

Clinical features

COX-2

Positive expression rate

P value

 

negative

positive

  

Ages

   

0.599

≤60

3

30

90.90%

 

> 60

2

15

88.20%

 

Sex

   

0.362

Male

4

27

87.10%

 

Female

1

18

94.70%

 

Pathologic type

   

0.022*

Squamous carcinoma

5

16

76.20%

 

Adencarcinoma

0

26

100%

 

Mixed type

0

3

100%

 

Tumor length

   

0.518

≤3 cm

2

14

87.50%

 

> 3 cm

3

31

91.20%

 

Level of Differentiation

   

0.258

Poor Differentiated

2

8

80%

 

Moderate and Well Differentiated

3

37

92.50%

 

TNM Stage

   

0.476

I-II

2

13

86.70%

 

III-IV

3

32

91.40%

 

Lymph node

   

0.699

N0

1

10

90.90%

 

N1-3

4

35

89.70%

 

*P < 0.05

Under the heading "Correlation of EGFR and COX-2 expression" The sentence reads: "As shown in Table seven, no correlation was found between COX-2 and EGFR protein expression (Χ 2 = 0.112, P = 0.555)."

But should have read: "As shown in Table seven, no correlation was found between COX-2 and EGFR protein expression (P > 0.05)."

Correct table seven (Table 5).
Table 5

(corrected table seven) Correlation of EGFR and COX-2 protein expression

  

EGFR

Total

  

negative

Positive

 

COX-2

negative

3

2

5

 

positive

24

21

45

 

Total

27

23

50

There was no significant relationship between COX-2 and EGFR. P > 0.05.

Notes

Authors’ Affiliations

(1)
Radiation Oncology, Tumor Center, West China Hospital, Sichuan University
(2)
Department of Pathology, West China Hospital, Sichuan University

References

  1. Li Feng, Liu Yongmei, Chen Huijiao, Liao Dianying, Shen Yali, Xu Feng, Wang Jin: EGFR and COX-2 protein expression in non-small cell lung cancer and the correlation with clinical features. Journal of Experimental & Clinical Cancer Research. 2011, 30: 27-10.1186/1756-9966-30-27.View ArticleGoogle Scholar

Copyright

© Li et al; licensee BioMed Central Ltd. 2011

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.